These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25756604)

  • 1. Long-term Course of Alzheimer Disease in Patients Treated According to the Dutch Dementia Guideline at a Memory Clinic: A "Real-Life" Study.
    Droogsma E; van Asselt D; van Steijn J; Diekhuis M; Veeger N; De Deyn PP
    Alzheimer Dis Assoc Disord; 2016; 30(1):53-9. PubMed ID: 25756604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.
    Droogsma E; van Asselt D; Diekhuis M; Veeger N; van der Hooft C; De Deyn PP
    Int Psychogeriatr; 2015 Aug; 27(8):1323-33. PubMed ID: 25779465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
    Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
    Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
    Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST
    J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer's disease patients.
    Bracco L; Bessi V; Padiglioni S; Marini S; Pepeu G
    J Alzheimers Dis; 2014; 40(3):737-42. PubMed ID: 24577458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort.
    Behl P; Lanctôt KL; Streiner DL; Black SE
    Int Psychogeriatr; 2008 Dec; 20(6):1141-59. PubMed ID: 18606043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clock Drawing Test for dementia of the Alzheimer's type: A comparison of three scoring methods in a memory disorders clinic.
    Brodaty H; Moore CM
    Int J Geriatr Psychiatry; 1997 Jun; 12(6):619-27. PubMed ID: 9215942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
    Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
    Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of suspected Alzheimer's disease patients by specialist physicians at the first visit in Spain: First Consultation Study.
    Martínez Lozano MD; Guzmán Quilo C;
    Expert Rev Neurother; 2011 May; 11(5):657-63. PubMed ID: 21539486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
    Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy.
    Wallin AK; Gustafson L; Sjögren M; Wattmo C; Minthon L
    Dement Geriatr Cogn Disord; 2004; 18(2):197-206. PubMed ID: 15211076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study.
    Calabria M; Geroldi C; Lussignoli G; Sabbatini F; Zanetti O
    Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.